Day: November 16, 2022

LONDON and PHOENIX, Nov. 16, 2022 (GLOBE NEWSWIRE) — AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced today the appointment of Sean McDonald to its Board of Directors which will now comprise five members. “We are pleased to welcome Sean to the board and believe his experience building and leading healthcare organizations and securing funding for early-stage companies will be invaluable to our mission at AccuStem,” said Wendy Blosser, Chief Executive Officer and board member of AccuStem. Sean joins the AccuStem board while serving as the CEO of Ocugenix, a therapeutics company focused on the development and commercialization of therapies for ocular diseases caused by excessive fibrosis and blood vessels in the eye. Sean served as a director...

HOUSTON, Nov. 16, 2022 (GLOBE NEWSWIRE) — Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the receipt of a formal notification from the Staff at The Nasdaq Stock Market, LLC (“Nasdaq”) on November 10, 2022 that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1). The Company was previously notified by the Staff at Nasdaq on August 9, 2022 that its common stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Listing Rules. Since then, the Staff at Nasdaq has determined that for 11 consecutive business days, from October 27, 2022 to November 10, 2022, the closing bid price of the Company’s...

— Featured speakers and KOLs include: Scott Tarriff, Herm Cukier, Dr. Richard Dutton, Dr. Prem Fort, Dr. TJ Gan, Dr. Andre Kalil, Dr. Joseph Pergolizzi and Dr. Eugene Vortsman — — Topics include the clinical and scientific rationale for the Company’s hospital-based products and pipeline programs: Enalare’s ENA-001, CAL02, BARHEMSYS®, BYFAVO® and landiolol — WOODCLIFF LAKE, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) — Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the following speakers and world-renowned Key Opinion Leaders will be featured at the Company’s Investor Day on Tuesday, December 6, 2022, at the Lotte New York Palace Hotel, at 8:00am ET:Scott Tarriff, President and Chief Executive Officer of Eagle Pharmaceuticals, and senior members of the Company’s clinical...

TORONTO, Nov. 16, 2022 (GLOBE NEWSWIRE) — EnviroGold Global Limited (CSE: NVRO | OTCQB: ESGLF |FSE: YGK) (“EnviroGold Global” or the “Company“), a Clean Technology Company accelerating the world’s transition to a circular-resource economy, is pleased to announce it has filed a patent for its proprietary process to efficiently recover precious and critical metals from refractory ores while completely neutralizing the acid-forming potential of waste (the “NVRO Process”). The Company plans to apply this technology to tailings as well as primary production streams worldwide. There are over 280 billion metric tonnes of mine tailings on the earth’s surface with a contained metal value that exceeds US$3.4T. McKinsey & Company reports that refractory ore represents 24% of current gold reserves and 22% of all gold resources globally,...

DEADLINE TO PARTICIPATE IN EARGO RIGHTS OFFERING IS TOMORROW, NOVEMBER 17, 2022: FOR U.S. HOLDERS WHO HOLD SHARES THROUGH A BROKERAGE ACCOUNT: 2:15 P.M., NEW YORK CITY TIME, ON NOVEMBER 17, 2022, SUBJECT TO ANY OTHER DEADLINES SET BY YOUR BROKER FOR U.S. REGISTERED HOLDERS: 5:00 P.M., NEW YORK CITY TIME, ON NOVEMBER 17, 2022Eargo stockholders should contact Morrow Sodali, Eargo’s information agent for the rights offering, for assistance in participating in the rights offering by calling (800) 662-5200. Eargo stockholders who own shares of Eargo common stock through a broker, dealer or nominee should contact the customer service department of their broker, dealer or nominee and request to speak to Corporate Actions to participate in the rights offering; Brokers, dealers and nominees may require their clients to complete subscription...

Figure 1 Drillhole Locations with block model (5) and topography.Figure 2 Long Section showing block model (6) and intercept locations.Figure 3 Cross SectionFigure 4 Cross SectionFigure 5 Cross SectionVANCOUVER, British Columbia, Nov. 16, 2022 (GLOBE NEWSWIRE) — NorthWest Copper (“NorthWest” or “the Company”) (TSX-V: NWST) (OTCQX: NWCCF) is pleased to announce the first results from the 2022 Stardust drilling program in the 421-Canyon Creek Skarn zone. These holes were designed to increase confidence in the high-grade mineralization at NorthWest’s 100% owned Stardust deposit. Stardust is located approximately 7 km from NorthWest’s 100% owned Kwanika deposit. Highlights from assays include:DDH22-SD-478D: 44.20 metres1 of 1.31% CuEq2 from 502.00 metresIncluding 21.10 metres at 2.41% CuEq from 523.10 metres Including...

Golar LNG Limited (“Golar” or “the Company”) reports Net income of $141.1 million and Adjusted EBITDA1 of $85.2 million for Q3 2022 (“Q3” or “the quarter”). FLNG Hilli customer elected to exercise optional capacity of 0.2 million tons per annum (“MTPA”) of Dutch Title Transfer Facility (“TTF”) linked production from 2023 to 2026. Entered into swap arrangements to hedge approximately 50% of Golar’s exposure to TTF linked FLNG Hilli production for Q4 2022, 100% of Golar’s exposure to 2023 TTF linked production, and 50% of Golar’s exposure to 2024 TTF linked production. Sold 8.0 million shares in Cool Company Ltd. (“CoolCo”) and 6.3 million shares in New Fortress Energy Inc. (“NFE”), raising net proceeds of $430 million in November. Strong customer development for FLNG growth...